Jazz Pharmaceuticals: Leukemia, Myeloid, Acute trials

The registry lists 12 Leukemia, Myeloid, Acute studies with Jazz Pharmaceuticals as lead sponsor. 0 are open to participants now and 6 have results posted.

Early Phase 1 1Phase 1 2Phase 2 4Phase 3 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaTerminatedNCT04571645Phase 3Results posted
• Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02873338Phase 2Results posted
• An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS PatientsCompletedNCT02238925Phase 2Results posted
• A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid LeukemiaCompletedNCT02056782Phase 1Results posted
• Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid LeukemiaCompletedNCT01696084Phase 3Results posted
• Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)CompletedNCT00822094Phase 2Results posted
• VYxeoS Liposomal Italian Observational Study iN the Real PracticeCompletedNCT06143839
• CPX-351 Real-World Effectiveness and Safety StudyCompletedNCT05169307
• A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedNCT04075747Phase 1
• A Post-Marketing Observational Study of VYXEOS™CompletedNCT03526926
• Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic ImpairmentWithdrawnNCT02269579Phase 2
• Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid LeukemiaCompletedNCT01843634Early Phase 1